收稿日期: 2020-04-03
网络出版日期: 2020-06-25
基金资助
CSCO-默克雪兰诺肿瘤研究基金(SCOREY-MX2015-045);国家自然科学基金面上项目(81573037);国家自然科学基金面上项目(81872523);上海市科委医学引导类项目(134119a6100);上海申康医院发展中心临床创新三年行动计划(16CR3084B);上海交通大学医学院高峰学科——临床医学研究型医师(20172009)
Anti-transcriptional intermediary factor 1-γ antibody serves as a serum biomarker for dermatomyositis accompanied by malignancy diseases
Received date: 2020-04-03
Online published: 2020-06-25
目的: 研究血清抗转录中介因子1-γ(transcriptional intermediary factor 1-γ, TIF1-γ)抗体在诊断皮肌炎(dermatomyositis, DM)和临床无肌病性皮肌炎(clinically amyopathic dermatomyositis, CADM)合并恶性肿瘤中的价值。方法: 2016年1月至2019年12月间,收集上海交通大学医学院附属瑞金医院皮肤科病房收治的223例DM和CADM患者[包括209例成人DM(107例)和CADM(102例),5例青少年DM(juvenile DM, JDM)和9例青少年JCADM(juvenile CADM, JCADM)]的临床资料。成人DM和成人CADM分别被分为恶性肿瘤组和无肿瘤组。初诊时血清用酶联免疫吸附测定法检测患者血清抗TIF1-γ抗体,分别比较成人DM和成人CADM患者中恶性肿瘤与无肿瘤患者之间抗TIF1-γ抗体的阳性率,进一步比较抗TIF1-γ抗体阳性与抗体阴性患者之间恶性肿瘤的发生率。结果: ①成人DM和CADM中恶性肿瘤共42例(20.1%),占前3位的分别是鼻咽癌、乳腺癌和肺癌。JDM和JCADM患者中无一例发生恶性肿瘤。②成人DM和CADM中有74例(74/209,35.4%)血清抗TIF1-γ抗体阳性,其中DM患者抗TIF1-γ抗体阳性率33.6%(36/107),CADM患者抗TIF1-γ抗体阳性率37.3%(38/102)。5例JDM患者中,无一例抗TIF1-γ抗体阳性;9例JCADM患者中,3例抗TIF1-γ抗体阳性。③成人DM中,恶性肿瘤患者的抗TIF1-γ抗体阳性率显著高于无肿瘤患者[26/35(74.3%)比10/72(13.9%), P<0.000 1];抗TIF1-γ抗体阳性患者恶性肿瘤的发生率显著高于阴性患者[26/36 (72.2%)比9/71 (12.7%), P<0.000 1]。成人CADM中,恶性肿瘤患者与无肿瘤患者之间抗TIF1-γ抗体的阳性率差异无统计学意义[4/7比34/95(35.8%), P=0.420];抗TIF1-γ抗体阳性与抗体阴性患者之间恶性肿瘤的发生率差异无统计学意义[4/38(10.5%)比3/64(4.7%), P=0.420]。结论: 抗TIF1-γ抗体阳性与成人DM患者恶性肿瘤的发生相关,而与成人CADM患者恶性肿瘤发生无关。抗TIF1-γ抗体可能是成人DM合并恶性肿瘤的血清标志物,对于抗TIF1-γ抗体阳性的成人DM患者需要加强恶性肿瘤筛查。
夏群力, 刁立诚, 吴海曦, 薛珂, 吴丹, 杜联军, 郑捷, 曹华, 黎皓 . 抗转录中介因子1-γ抗体是成人皮肌炎合并恶性肿瘤的血清学标志物[J]. 诊断学理论与实践, 2020 , 19(03) : 274 -278 . DOI: 10.16150/j.1671-2870.2020.03.013
Objective: To explore significance of anti-transcriptional intermediary factor 1-γ (TIF1-γ) antibody detection in diagnosing ermatomyositis (DM) malignancy or clinically amyopathic dermatomyositis (CADM) accompanied by malignancy diseases. Methods: A total of hospitalized 223 patients were enrolled at Department of Dermatology, Ruijin Hospital during Jan. 2016 to Dec. 2019, including 107 cases of adult DM, 102 cases of adult CADM, 5 cases of juvenile DM, and 9 cases of juvenile CADM. DM patients were divided into malignant DM group and non-malignant DM group, and so were the CADM patients. Enzyme-linked immunosorbent assay(ELISA) was used to detect serum anti-TIF1-γ antibodies in patients at first visit. The positive rates of anti-TIF1-γ antibody were compared between malignant DM group and non-malignant DM as well as between malignant CADM group and non-malignant CADM group. Results: It revealed that 35 adult DM and 7 adult CADM patients were diagnosed as having malignant neoplasia, and nasopharyngeal carcinoma, breast cancer and lung cancer were on the top three of cancer-associated myositis in our cohort, however, there was no malignancy detected in JDM and JCADM patients. Seventy-four (35.4%) adult patients had serum anti-TIF1-γ antibody detected, including 36 cased of DM (33.6%) and 38 cases of CADM (37.3%). Serum anti-TIF1-γ antibody was positive in 3 cases of JCADM (33.3%), but none in total of 5 cases of JDM. The positive rate of anti-TIF1-γ antibody in DM patients with malignant tumor was significantly higher than those without malignant tumor[26/35(74.3%) vs 10/72(13.9%), P<0.000 1]. The incidence of malignant tumor in patients with positive anti-TIF1-γ antibody was significantly higher than those with negative antibody[26/36(72.2%) vs 9/71(12.7%), P<0.000 1]. However there was no significant difference in the positive rate of anti-TIF1-γ antibody between patients with malignant tumor and without malignant tumor [4/7 vs 34/95(35.8%), P=0.420] in adult CADM. There was no statistically significant difference in the incidence of malignancy between anti-TIF1-γ antibody-positive and antibody-negative patients[4/38 (10.5%) vs 3/64(4.7%), P=0.420]. Conclusions: Serum anti-TIF1-γ antibody correlates with the occurrence of malignancy diseases in DM, but has no relationship with malignancy diseases in CADM. Thus, anti-TIF1-γ antibody might be the serum biomarker for DM associated with malignancy, and oncology screening should be intensified in adult DM patients with positive anti-TIF1-γ antibody.
[1] | Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study[J]. Br J Cancer, 2001, 85(1):41-45. |
[2] | Zhang W, Jiang SP and Huang L. Dermatomyositis and malignancy: Aretrospective study of 115 cases[J]. Eur Rev Med Pharmacol Sci, 2009, 13(2):77-80. |
[3] | Azuma K, Yamada H, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis[J]. Mod Rheumatol, 2011, 21(2):178-183. |
[4] | Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study[J]. Lancet, 2001, 357(9250):96-100. |
[5] | Chen D, Yuan S, Wu X, et al. Incidence and predictive factors for malignancies with dermatomyositis: A cohort from southern China[J]. Clin Exp Rheumatol, 2014, 32(5):615-621. |
[6] | Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts[J]. Medicine (Baltimore), 2018, 97(2):e9639. |
[7] | Wang J, Guo G, Chen G, et al. Meta-analysis of the association of dermatomyositis and polymyositis with cancer[J]. Br J Dermatol, 2013, 169(4):838-847. |
[8] | Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kdprotein is associated with dermatomyositis[J]. Arthritis Rheum, 2006, 54(11):3682-3689. |
[9] | Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140kDa nuclear proteins in patients with dermatomyositis: An association with malignancy[J]. Rheumatology (Oxford), 2007, 46(1):25-28. |
[10] | Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7):344-347. |
[11] | Sontheimer RD, Miyagawa S. Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis[J]. J Am Acad Dermatol, 2003, 48(5):797-798. |
[12] | Chen DY, Chen YM, Lan JL, et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: The Epstein-Barr virus connection?[J]. J Clin Virol, 2010, 49(4):290-295. |
[13] | Ogawa-Momohara M, Muro Y, Mitsuma T, et al. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients[J]. Clin Exp Rheumatol, 2018, 36(6):990-995. |
[14] | Selva-O’Callaghan A, Trallero-Araguás E, Grau-Junyent JM, et al. Malignancy and myositis: Novel autoantibodies and new insights[J]. Curr Opin Rheumatol, 2010, 22(6):627-632. |
[15] | Ueda-Hayakawa I, Hamaguchi Y, Okiyama N, et al. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: Clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy[J]. Br J Dermatol, 2019, 180(4):881-887. |
[16] | Ueki M, Kobayashi I, Takezaki S, et al. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies[J]. Mod Rheumatol, 2019, 29(2):351-356. |
[17] | Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult-Japanese patients with dermatomyositis: A multicenter cross-sectional study[J]. Arch Dermatol, 2011, 147(4):391-398. |
[18] | Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: Their clinical and pathogenic significance in disease expression[J]. Rheumatology(Oxford), 2009, 48(6):607-612. |
/
〈 |
|
〉 |